Disposition and metabolism of [(14)C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats

Levomilnacipran is approved in the US for the treatment of major depressive disorder in adults. We characterized the metabolic profile of levomilnacipran in humans, monkeys, and rats after oral administration of [(14)C]-levomilnacipran. In vitro binding of levomilnacipran to human plasma proteins wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunner, Valérie, Maynadier, Bernadette, Chen, Laishun, Roques, Louise, Hude, Isabelle, Séguier, Sébastien, Barthe, Laurence, Hermann, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484650/
https://www.ncbi.nlm.nih.gov/pubmed/26150694
http://dx.doi.org/10.2147/DDDT.S80886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484650/
https://www.ncbi.nlm.nih.gov/pubmed/26150694
http://dx.doi.org/10.2147/DDDT.S80886

Ejemplares similares